Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

被引：0
|
作者：
Santoro, Armando [1 ,2 ]
Johnson, Nathalie A. [3 ]
Savage, Kerry J. [4 ]
Avigdor, Abraham [5 ]
Bazargan, Ali [6 ,7 ]
Borchmann, Peter [8 ]
Gasiorowski, Robin [9 ]
Gregory, Gareth P. [10 ]
Herishanu, Yair [11 ]
Madan, Sumit [12 ]
Minuk, Leonard [13 ,14 ]
Musuraca, Gerardo [15 ]
West, Rachel Marceau [16 ]
Pillai, Pallavi [16 ]
Marinello, Patricia [16 ]
Zinzani, Pier Luigi [17 ,18 ]
机构：
[1] Humanitas Univ, Pieve Emanuele, Milan, Italy
[2] IRCCS Humanitas Res Hosp Humanitas Canc Ctr Rozza, Milan, Italy
[3] Jewish Gen Hosp, Montreal, PQ, Canada
[4] BC Canc, Div Med Oncol, Vancouver, BC, Canada
[5] Sheba Med Ctr Tel HaShomer, Ramat Gan, Israel
[6] Univ Melbourne, Melbourne, Vic, Australia
[7] St Vincents Hosp, Fitzroy, Vic, Australia
[8] Univ Hosp Cologne, Cologne, Germany
[9] Univ Sydney, Concord Hosp, Concord, NSW, Australia
[10] Monash Univ, Sch Clin Sci Monash Hlth, Melbourne, Vic, Australia
[11] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[12] Banner MD Anderson Canc Ctr, Gilbert, AZ USA
[13] CancerCare Manitoba, Winnipeg, MB, Canada
[14] Univ Manitoba, Winnipeg, MB, Canada
[15] IRCCS Ist Romagnolo Tumori IRST Dino Amadori, Meldola, Italy
[16] Merck & Co Inc, Rahway, NJ USA
[17] Univ Bologna Ist Ematol Seragnoli, IRCCS Azienda Osped, Bologna, Italy
[18] Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182536
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Kalakonda, Nagesh
    Cavallo, Federica
    Follows, George
    Goy, Andre
    Vermaat, Joost S. P.
    Casasnovas, Olivier
    Lavee, Orly
    Maerevoet, Marie
    Zijlstra, Josee
    Bakhshi, Sameer
    Bouabdallah, Reda
    Choquet, Sylvain
    Gurion, Ronit
    Hill, Brian
    Jaeger, Ulrich
    Sancho, Juan-Manuel
    Schuster, Michael
    Thieblemont, Catherine
    De la Cruz, Fatima
    Egyed, Miklos
    Mishra, Sourav
    Offner, Fritz
    Vassilakopoulos, Theodoros
    Warzocha, Krzysztof
    McCarthy, Daniel
    Ma, Xiwen
    Corona, Kelly
    Saint-Martin, Jean-Richard
    Joshi, Anita
    Shah, Jatin
    Van den Neste, Eric
    Canales, Miguel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
  • [22] Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008
    Lavie, David
    Timmerman, John
    Garcia-Sanz, Ramon
    Kim, Won Seog
    Kim, Tae Min
    Avigdor, Abraham
    Dierickx, Daan
    Jagadeesh, Deepa
    Molin, Daniel L.
    Ozcan, Muhit
    Sevindik, Omur Gokmen
    Saeed, Hayder
    Sidi, Yulia
    Pillai, Pallavi
    Marinello, Patricia
    Herrera, Alex F.
    BLOOD, 2023, 142
  • [23] Safety and Efficacy of Vibostolimab and Pembrolizumab in Patients with Relapsed or Refractory Hematologic Malignancies: A Multicohort, Open-Label, Phase 2 Study
    Yusuf, Rushdia
    Jemielita, Thomas
    Marinello, Patricia
    BLOOD, 2021, 138
  • [24] Epcoritamab versus standard of care in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) - a phase 3 study (EPCORE DLBCL-1)
    Hess, G.
    Thieblemont, C.
    Clausen, M. R.
    Lugtenburg, P.
    Balari, Sureda A.
    Zinzani, P. L.
    Wu, J.
    Finn, L.
    Vindelov, S. D.
    Fox, C. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 192 - 193
  • [25] A MULTICENTER PHASE II STUDY OF BENDAMUSTINE WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Kim, W. S.
    Ando, K.
    Niitsu, N.
    Ogura, M.
    Takahashi, N.
    Uike, N.
    Eom, H. Seok
    Chae, Y. S.
    Tobinai, K.
    Terauchi, T.
    Tateishi, U.
    Tatsumi, M.
    Suh, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 94 - 94
  • [26] A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Kambhampati, Swetha
    Kallam, Avyakta
    Borogovac, Azra
    Chen, Lu
    Puverel, Sandrine
    Johnson, Jennifer
    Melgar, Ivana
    Baird, John H.
    Danilov, Alexey
    Godfrey, James
    Khan, Niloufer
    Mei, Matthew
    Phillips, Tycel J. J.
    Siddiqi, Tanya
    Shouse, Geoffrey
    Zain, Jasmine
    Kwak, Larry W.
    Rosen, Steven T.
    Forman, Stephen J.
    Song, Joo Y.
    Herrera, Alex F.
    Budde, Elizabeth
    BLOOD, 2024, 144 : 17421 - 17422
  • [27] A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Czuczman, Myron S.
    Trneny, Marek
    Davies, Andrew
    Rule, Simon
    Linton, Kim M.
    Wagner-Johnston, Nina
    Gascoyne, Randy D.
    Slack, Graham W.
    Brousset, Pierre
    Eberhard, David A.
    Hernandez-Ilizaliturri, Francisco J.
    Salles, Gilles
    Witzig, Thomas E.
    Zinzani, Pier Luigi
    Wright, George W.
    Staudt, Louis M.
    Yang, Yandan
    Williams, P. Mickey
    Lih, Chih-Jian
    Russo, Jacqueline
    Thakurta, Anjan
    Hagner, Patrick
    Fustier, Pierre
    Song, Dale
    Lewis, Ian D.
    CLINICAL CANCER RESEARCH, 2017, 23 (15) : 4127 - 4137
  • [28] Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
    Lenz, Georg
    Hawkes, Eliza
    Verhoef, Gregor
    Haioun, Corinne
    Thye, Lim Soon
    Heo, Dae Seog
    Ardeshna, Kirit
    Chong, Geoffrey
    Christensen, Jacob Haaber
    Shi, Vivian
    Lippert, Susanne
    Niemeyer, Florian
    Piraino, Paolo
    Pena, Carol Elaine
    Buvaylo, Viktoriya
    Childs, Barrett H.
    Gorbatchevsky, Igor
    Salles, Gilles A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Chen, Robert W.
    Ansel, Stephen Maxted
    Zinzani, Pier Luigi
    Vacirca, Jeffrey L.
    Lopez-Guillermo, Armando
    Hutchings, Martin
    Jurczak, Wojciech
    Hess, Georg
    Le Gouill, Steven
    Offner, Fritz
    Santoro, Armando
    Salles, Gilles A.
    Stypinski, Darla
    Laird, Douglas
    Pavlov, Dmitri
    Andreola, Giovanna
    Fly, Kolette D.
    Woolfson, Adrian
    Collins, Graham P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
    Ma, Xinran
    Li, Ling
    Zhang, Lei
    Fu, Xiaorui
    Li, Xin
    Wang, Xinhua
    Wu, Jingjing
    Sun, Zhenchang
    Zhang, Xudong
    Feng, Xiaoyan
    Chang, Yu
    Zhou, Zhiyuan
    Nan, Feifei
    Zhang, Jieming
    Li, Zhaoming
    Zhang, Mingzhi
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 275 - 284
12345